SCHEMBL4143701

SCHEMBL4143701

N#Cc1c(Cl)c(-c2ccsc2)nn(Cc2ccc(F)cc2)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 5/20 0.46
ADORA2A P29274 3/20 0.43
HTT P42858 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
PKM P14618 2/20 0.41
MITF O75030 1/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
HSD17B10 Q99714 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
RET P07949 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4137219 0.88 ADORA1 (0.45) ADORA1ADORA2AHTTNPSR1PKM
SCHEMBL4143666 0.79 ADORA2A (0.41) ADORA1ADORA2AHTTNPSR1ALDH1A1
SCHEMBL13905624 0.77 ADORA2A (0.40) ADORA1ADORA2AHTTNPSR1ALDH1A1
SCHEMBL13905625 0.74 ADORA2A (0.39) ADORA1ADORA2APKMALDH1A1KDM4E
SCHEMBL4125999 0.70 USP2 (0.45) ADORA1ADORA2ANPSR1PKMALDH1A1
SCHEMBL4123420 0.70 PDE4A (0.44) ADORA1ADORA2APKMKDM4EHSD17B10
SCHEMBL4142975 0.67 ADORA1 (0.40) ADORA1ADORA2AALDH1A1KDM4EMEN1
SCHEMBL4136431 0.67 CNR2 (0.54)
SCHEMBL13905617 0.67 MERTK (0.41) ADORA1ADORA2APTGES
SCHEMBL4126223 0.66 GRM2 (0.40) ADORA1ADORA2APTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI POLR2E, POLR2H, POLI ADORA1 3760/4885ADORA2A 2513/4885HTT 4552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.